Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.

Horwitz JA, Bar-On Y, Lu CL, Fera D, Lockhart AAK, Lorenzi JCC, Nogueira L, Golijanin J, Scheid JF, Seaman MS, Gazumyan A, Zolla-Pazner S, Nussenzweig MC.

Cell. 2017 Aug 10;170(4):637-648.e10. doi: 10.1016/j.cell.2017.06.048. Epub 2017 Jul 27.

2.

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.

Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H, Cesar Lorenzi JC, Halper-Stromberg A, Toth I, Piechocka-Trocha A, Gristick HB, van Gils MJ, Sanders RW, Wang LX, Seaman MS, Burton DR, Gazumyan A, Walker BD, West AP Jr, Bjorkman PJ, Nussenzweig MC.

Sci Transl Med. 2017 Jan 18;9(373). pii: eaal2144. doi: 10.1126/scitranslmed.aal2144.

3.

Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA.

Lorenzi JC, Cohen YZ, Cohn LB, Kreider EF, Barton JP, Learn GH, Oliveira T, Lavine CL, Horwitz JA, Settler A, Jankovic M, Seaman MS, Chakraborty AK, Hahn BH, Caskey M, Nussenzweig MC.

Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):E7908-E7916. Epub 2016 Nov 21. Erratum in: Proc Natl Acad Sci U S A. 2017 Jan 17;:.

4.

Expanding the Host Range of Hepatitis C Virus through Viral Adaptation.

von Schaewen M, Dorner M, Hueging K, Foquet L, Gerges S, Hrebikova G, Heller B, Bitzegeio J, Doerrbecker J, Horwitz JA, Gerold G, Suerbaum S, Rice CM, Meuleman P, Pietschmann T, Ploss A.

MBio. 2016 Nov 8;7(6). pii: e01915-16. doi: 10.1128/mBio.01915-16.

5.

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.

Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, Feldmann A, Braunschweig M, Nogueira L, Oliveira T, Shimeliovich I, Patel R, Burke L, Cohen YZ, Hadrigan S, Settler A, Witmer-Pack M, West AP Jr, Juelg B, Keler T, Hawthorne T, Zingman B, Gulick RM, Pfeifer N, Learn GH, Seaman MS, Bjorkman PJ, Klein F, Schlesinger SJ, Walker BD, Hahn BH, Nussenzweig MC, Caskey M.

Nature. 2016 Jul 28;535(7613):556-60. Epub 2016 Jun 22.

6.

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.

Lu CL, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, Horwitz JA, Nogueira L, Golijanin J, Gazumyan A, Ravetch JV, Caskey M, Chakraborty AK, Nussenzweig MC.

Science. 2016 May 20;352(6288):1001-4. doi: 10.1126/science.aaf1279. Epub 2016 May 5.

7.

Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC.

Nature. 2016 Jul 28;535(7613):580. doi: 10.1038/nature17642. Epub 2016 Mar 23. No abstract available.

PMID:
27007847
8.

A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.

Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A, Sanders RW, Moore JP, Bjorkman PJ, Seaman MS, Walker BD, Klein F, Nussenzweig MC.

PLoS Pathog. 2015 Oct 30;11(10):e1005238. doi: 10.1371/journal.ppat.1005238. eCollection 2015 Oct.

9.

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC.

Nature. 2015 Jun 25;522(7557):487-91. doi: 10.1038/nature14411. Epub 2015 Apr 8. Erratum in: Nature. 2016 Jul 28;535(7613):580.

10.

Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice.

Scull MA, Shi C, de Jong YP, Gerold G, Ries M, von Schaewen M, Donovan BM, Labitt RN, Horwitz JA, Gaska JM, Hrebikova G, Xiao JW, Flatley B, Fung C, Chiriboga L, Walker CM, Evans DT, Rice CM, Ploss A.

Hepatology. 2015 Jul;62(1):57-67. doi: 10.1002/hep.27773. Epub 2015 Apr 15.

11.

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.

Klein F, Nogueira L, Nishimura Y, Phad G, West AP Jr, Halper-Stromberg A, Horwitz JA, Gazumyan A, Liu C, Eisenreich TR, Lehmann C, Fätkenheuer G, Williams C, Shingai M, Martin MA, Bjorkman PJ, Seaman MS, Zolla-Pazner S, Karlsson Hedestam GB, Nussenzweig MC.

J Exp Med. 2014 Nov 17;211(12):2361-72. doi: 10.1084/jem.20141050. Epub 2014 Nov 10.

12.

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC.

Cell. 2014 Aug 28;158(5):989-999. doi: 10.1016/j.cell.2014.07.043. Epub 2014 Aug 14.

13.

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice.

Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, Eisenreich TR, Malbec M, Gravemann S, Billerbeck E, Dorner M, Büning H, Schwartz O, Knops E, Kaiser R, Seaman MS, Wilson JM, Rice CM, Ploss A, Bjorkman PJ, Klein F, Nussenzweig MC.

Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16538-43. doi: 10.1073/pnas.1315295110. Epub 2013 Sep 16.

14.

Completion of the entire hepatitis C virus life cycle in genetically humanized mice.

Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, Vogt A, Catanese MT, Satoh T, Kawai T, Akira S, Law M, Rice CM, Ploss A.

Nature. 2013 Sep 12;501(7466):237-41. doi: 10.1038/nature12427. Epub 2013 Jul 31.

15.

Characterization of human antiviral adaptive immune responses during hepatotropic virus infection in HLA-transgenic human immune system mice.

Billerbeck E, Horwitz JA, Labitt RN, Donovan BM, Vega K, Budell WC, Koo GC, Rice CM, Ploss A.

J Immunol. 2013 Aug 15;191(4):1753-64. doi: 10.4049/jimmunol.1201518. Epub 2013 Jul 5.

16.

Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines.

Vogt A, Scull MA, Friling T, Horwitz JA, Donovan BM, Dorner M, Gerold G, Labitt RN, Rice CM, Ploss A.

Virology. 2013 Sep;444(1-2):1-11. doi: 10.1016/j.virol.2013.05.036. Epub 2013 Jun 16.

17.

Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies.

Diskin R, Klein F, Horwitz JA, Halper-Stromberg A, Sather DN, Marcovecchio PM, Lee T, West AP Jr, Gao H, Seaman MS, Stamatatos L, Nussenzweig MC, Bjorkman PJ.

J Exp Med. 2013 Jun 3;210(6):1235-49. doi: 10.1084/jem.20130221. Epub 2013 May 27.

18.

Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein.

Horwitz JA, Dorner M, Friling T, Donovan BM, Vogt A, Loureiro J, Oh T, Rice CM, Ploss A.

Virology. 2013 Apr 25;439(1):23-33. doi: 10.1016/j.virol.2013.01.019. Epub 2013 Feb 26.

19.

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio P, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC.

Nature. 2012 Dec 6;492(7427):118-22. doi: 10.1038/nature11604. Epub 2012 Oct 24.

20.

A genetically humanized mouse model for hepatitis C virus infection.

Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A.

Nature. 2011 Jun 8;474(7350):208-11. doi: 10.1038/nature10168.

21.

Biological performance of biodegradable amino acid-based poly(ester amide)s: Endothelial cell adhesion and inflammation in vitro.

Horwitz JA, Shum KM, Bodle JC, Deng M, Chu CC, Reinhart-King CA.

J Biomed Mater Res A. 2010 Nov;95(2):371-80. doi: 10.1002/jbm.a.32858.

PMID:
20629024
22.

Chorioretinal lesions in nonfatal cases of West Nile virus infection.

Hershberger VS, Augsburger JJ, Hutchins RK, Miller SA, Horwitz JA, Bergmann M.

Ophthalmology. 2003 Sep;110(9):1732-6.

PMID:
13129870
23.

First report of prenatal biochemical diagnosis of Lowe syndrome.

Suchy SF, Lin T, Horwitz JA, O'Brien WE, Nussbaum RL.

Prenat Diagn. 1998 Nov;18(11):1117-21.

PMID:
9854717
24.

Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists.

Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA.

J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41.

PMID:
8968334
25.

Transscleral stimulator for the visual-evoked response.

Horwitz JA, Dawson WW, Rubin ML.

Am J Ophthalmol. 1973 Sep;76(3):395-6. No abstract available.

PMID:
4728566
26.

Cystoid macular edema: histopathologic and angiographic correlations. A clinicopathologic case report.

Newsom WA, Hood CI, Horwitz JA, Fine SL, Sewell JH.

Trans Am Acad Ophthalmol Otolaryngol. 1972 Jul-Aug;76(4):1005-9. No abstract available.

PMID:
4666929
27.

Episcleral nodule in systemic vasculitis.

Horwitz JA, Worthen DM.

Ann Ophthalmol. 1972 Jun;4(6):482-3. No abstract available.

PMID:
4402259

Supplemental Content

Loading ...
Support Center